跳至主要内容
临床试验/NCT00559169
NCT00559169撤回不适用

Study of Verapamil in Refractory Catamenial Epilepsy

University Health Network, Toronto2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2009年2月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
撤回
入组人数
12
试验地点
2
主要终点
the percent reduction in seizure frequency

研究概览

简要总结

One in 3 epilepsy patients have refractory seizures. This drug resistance is likely related to the over expression of multidrug resistance proteins (MDR). Progesterone is a known inhibitor of MDRs and the low level of this hormone during the menstrual cycle may exacerbate seizures, perhaps explaining catamenial epilepsy; i.e. seizures occurring during the menstrual cycle. Verapamil suppresses seizures in animal models of epilepsy perhaps by inhibiting MDRs and thus may help patients with refractory seizures. If the study shows improved seizure control, the results will help establish the role of MDRs in refractory epilepsy.

研究设计

研究类型
Interventional
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • at least 2 seizures per month
  • more than 50% of the seizures occur 7 days before or 7 days after the onset of menses
  • patient of the Toronto Western Hospital Epilepsy Clinic

排除标准

  • cardiovascular history

结局指标

主要结局

the percent reduction in seizure frequency

时间窗: 3 months

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验